男女羞羞视频在线观看,国产精品黄色免费,麻豆91在线视频,美女被羞羞免费软件下载,国产的一级片,亚洲熟色妇,天天操夜夜摸,一区二区三区在线电影
Global EditionASIA 中文雙語Fran?ais
China
Home / China / National affairs

Civil code will strengthen research ethics

By Zhang Zhihao | China Daily | Updated: 2020-05-28 09:42
Share
Share - WeChat
A staff worker operates a gene sequencer at a BGI Genomics facility in Qingdao, Shandong province, on May 29, 2018. [Photo/Asia News Photo]

Complex issue

There is still no international consensus on the regulation of human germ cells-such as sperm and ovain genetic engineering, even though governments, institutions and international organizations issued more than 60 statements related to the ethics of the technology between 2014 and 2018, according to a study published in the scientific publication The CRISPR Journal.

The study said the problem partly stems from the divergence of germ cell engineering into basic research, clinical research and clinical applications, because they are subject to varying degrees of regulation in different countries.

For example, basic germ cell research is prohibited in Germany, Italy and Switzerland.

However, in countries such as China, Israel, Singapore, Sweden, the United Kingdom and parts of the United States, scientists are allowed to create genetically modified embryos for research, but they can only be studied during the first 14 days of their development in vitro.

To further complicate matters, many regulations are "unnecessarily vague and obsolete", the journal said. "Limitations must be spelled out in statutory and regulatory instruments that are sufficiently clear to allow scientists to regulate their conduct based on those provisions."

In a column in Guangming Daily last year, Li Xin, director of the Center of Science and Technology Laws at Capital Normal University in Beijing, said the paramount question on any regulation related to human gene editing is how to ensure the technology is used in an appropriate, justified manner.

"Tackling this question is like opening a can of worms, leading to a range of sensitive issues," she said.

For instance, gene editing may be the only solution for patients with severe congenital disorders, but who has the authority to approve such a procedure and conduct experiments to edit the fundamental blueprint of life?

If gene editing is allowed for therapeutic treatments, what is to stop people from abusing it to augment their own bodies or those of their offspring?

"The line between augmentation and treatment is blurred. It depends on whether the procedure is necessary for someone's well-being-but well-being itself is also a vague concept," Li said.

"In this case, the purpose of the law is to fill the gap between theoretical speculation and practical measures with procedures, rights, responsibilities and legal obligations."

Yuan Lanfeng, an associate researcher at the National Research Center for Microscale Material Science in Hefei, Anhui province, said if gene augmentation ever existed, the rich and powerful would inevitably abuse it to gain an unfair biological advantage.

"If China does not have a law related to gene editing, then it will have no legal basis to stop those attempts," he said. "That would be detrimental to building China's image as a responsible nation."

Mao Yonghui, a senior nephrologist and a member of the ethical review committee at The Beijing Hospital, said that with the advent of the CRISPR-Cas9 gene-editing technique-in which the cell's genome can be cut at a desired spot-manipulating genetic material has never been easier or more accessible, because people can get the instructions and equipment from the internet, just like a chemistry set.

"This accessibility also makes regulating the technology incredibly difficult," she said. "We must ensure scientific research and exploration are done responsibly and abide by the law. Only then can we ensure the these endeavors benefit humanity."

|<< Previous 1 2 3 4 5 6 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 苏尼特右旗| 景谷| 永顺县| 长春市| 双柏县| 闽侯县| 邯郸县| 承德县| 库尔勒市| 陇川县| 鄄城县| 本溪市| 宁波市| 锦屏县| 长阳| 舒兰市| 都昌县| 清新县| 富宁县| 松潘县| 阳新县| 金华市| 边坝县| 合肥市| 昌江| 郎溪县| 黑水县| 抚顺县| 灵宝市| 平泉县| 松溪县| 察隅县| 黄大仙区| 包头市| 甘泉县| 皋兰县| 景东| 三门峡市| 泾川县| 兴文县| 兴山县| 奉贤区| 关岭| 绥棱县| 甘南县| 民权县| 海晏县| 马山县| 封丘县| 阿鲁科尔沁旗| 灌南县| 马公市| 南汇区| 贵港市| 托克逊县| 达拉特旗| 开鲁县| 南郑县| 荔波县| 奎屯市| 贞丰县| 全椒县| 施秉县| 板桥市| 合江县| 孙吴县| 南雄市| 石柱| 南安市| 团风县| 鹤山市| 东安县| 二连浩特市| 元阳县| 北碚区| 武汉市| 盐亭县| 甘南县| 两当县| 新余市| 甘谷县| 大姚县|